O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)
暂无分享，去创建一个
M. Buti | P. Marcellin | R. Idilman | D. Samuel | S. Lim | G. Foster | K. Agarwal | R. Mehta | W. Tak | R. Flisiak | Chuan‐Mo Lee | S. Strasser | F. Tabak | G. Subramanian | Lanjia Lin | Phillip Dinh | E. Martins | P. Charuworn | J. Petersen | L. Morano | M. Elkhashab | S. Ahn | W. Chuang | S. Fung | A. Hui | G. Gaeta | F. Căruntu | G. Papatheodoridis | J. McHutchinson | Xiaoli Ma | H. Chan